Antiviral Treatment IMC-1 Shows Promise in Phase 2 Fibromyalgia Trial

Antiviral Treatment IMC-1 Shows Promise in Phase 2 Fibromyalgia Trial
IMC-1, a combination treatment of two drugs targeting the herpes virus, may be a safe and effective treatment for patients with fibromyalgia, according to the results of a Phase 2 trial developed by Innovative Med Concepts. Results were published in an article titled “A Famciclovir + Celecoxib Combination Treatment Is Safe And Efficacious In The Treatment Of Fibromyalgia” in the Journal of Pain Research. “Infections and other stressors have been implicated in the development of fibromyalgia,” researchers wrote in their report. “We hypothesized that these stressors could result in recurrent reactivations of latent herpes virus infections, which could lead to the development of fibromyalgia. This study evaluated … IMC-1, active against suspected herpes virus reactivation and infection, for the treatment of fibromyalgia.” The PRID-201 study (NCT01850420) enrolled 143 patients with fibromyalgia at 12 research centers in the U.S. to evaluate the effects of IMC-1 — a combination treatment of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib (brand name Celebrex). Results showed that, after 16 weeks of treatment, patients receiving IMC-1 had a decrease in fibromyalgia-associated pain compared to patients on a plac
Subscribe or to access all post and page content.